Elsevier

European Journal of Cancer

Volume 44, Issue 15, October 2008, Pages 2312-2318
European Journal of Cancer

Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas

https://doi.org/10.1016/j.ejca.2008.06.042Get rights and content

Abstract

Drug resistance is believed to cause treatment failure in patients with metastatic colorectal carcinoma (CRC). Resistance to chemotherapy can involve different processes, including apoptosis, whose extrinsic pathway is regulated by expression of death-inducing TRAIL-R1 and -R2 and inhibitory TRAIL-R3 and -R4 cell surface receptors. Therefore, we investigated whether variations in their expression could influence the response to 5-Fluorouracil (5-FU) in metastatic CRC. We analysed TRAIL-R 1, -2, -3 and -4 expression by immuno-histochemistry in CRC, using tissue micro arrays, and found that concomitant low/medium TRAIL-R1 and high TRAIL-R3 expression in primary CRC is significantly associated with a poor response to 5-FU-based first-line chemotherapy and with shorter progression-free survival. Specifically, the median progression-free survival was 3.1 months (poor prognostic group) versus 10.1 in the good prognostic group. Thus, the combination of TRAIL-R1 and TRAIL-R3 expression might represent a predictive and prognostic factor of the response to 5-FU-based first-line chemotherapy in patients with metastatic CRC.

Introduction

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a type II transmembrane protein that belongs to the tumour necrosis factor (TNF) superfamily. TRAIL activates apoptosis through the death receptors TRAIL-R1 (DR4) or TRAIL-R2 (DR5/KILLER) which carry cytoplasmic death domains. TRAIL also binds to two other membrane-bound receptors, TRAIL-R3 (DcR1/TRID) and TRAIL-R4 (DcR2/TRUNDD), which cannot transmit the apoptotic signal because they lack a functional intra-cytoplasmic domain. Consequently, TRAIL-R3 and TRAIL-R4 are thought to protect cells from TRAIL-induced apoptosis by acting as decoy receptors and thus interfering with the binding of the pro-apoptotic TRAIL-R1 and -R2.1 Importantly, unlike other TNF family members, TRAIL kills a wide variety of tumour cells with limited effects on normal tissues invivo.2, 3 This finding has aroused a great interest in the development of TRAIL-targeted therapies, and currently several clinical trials are being carried out in cancer patients.4, 5

Colorectal cancer (CRC) is the second most frequent cause of cancer death in Europe and United States. Chemotherapeutic agents can improve survival in patients with CRC, and 5-Fluorouracil (5-FU)-based chemotherapy, modulated with folinic acid, has long been a standard regimen. To enhance its efficiency in CRC patients, 5-FU is often administered in combination with other chemotherapeutic agents, such as oxaliplatin or irinotecan. Moreover, molecularly targeted therapies against epidermal growth factor receptor (such as cetuximab) and vascular endothelial growth factor (such as bevacizumab) have also shown promising effects in CRC.6, 7 However, despite the increasing therapeutic options, drug resistance remains a major problem for the treatment of this disease. As the ultimate goal of cytotoxic chemotherapies is to induce death of tumour cells, the presence of an imbalance between functional and decoy TRAIL receptors may be one of the mechanisms involved in the development of drug resistance. Preclinical data have shown that the use of TRAIL in combination with chemotherapeutic agents, such as 5-FU, CPT-11 or doxorubicin, sensitises CRC cells to apoptosis,8, 9 possibly through over-expression of TRAIL-R2.10 Conversely, over-expression of TRAIL-R3 or -R4 has been correlated with resistance to apoptosis.11, 12 Therefore, invivo analysis of TRAIL receptors’ expression in CRC tumour samples might be of clinical relevance. To this aim we analysed, using tissues micro arrays, TRAIL-R1 to -R4 expression in metastatic CRC of patients treated with 5-FU-based chemotherapy as the first-line treatment. We then correlated these findings with response to treatment, disease progression and survival.

Section snippets

Patients and treatment

For this study, we selected 60 patients with metastatic CRC who were enrolled in controlled trials to evaluate the effect of first-line 5-FU-based chemotherapy at the CRLC Val d’Aurelle-Paul Lamarque Cancer Centre in Montpellier, France, between 1991 and 2002. All our patients had a histological diagnosis of advanced colorectal adenocarcinoma with hepatic metastases either at the time of the diagnosis (i.e. synchronous disease) or after resection of the primary tumour (i.e. metachronous

TRAIL receptors’ expression in primary CRC and hepatic metastases

In primary CRC and hepatic metastases, the four TRAIL receptors were localised mainly in the cytoplasm (Fig. 1a), and their expression was quite variable amongst the different samples. Therefore, we decided to rank our samples in three different classes (low, medium and high) according to the number of positive cells for each TRAIL receptor (Fig. 1b). We then looked at the distribution of the three classes (Fig. 2) and observed that, in both primary CRC and hepatic metastases, the decoy

Discussion

Drug resistance remains a major issue in cancer treatment. In this study, we explored the potential role of the expression level of the four TRAIL receptors in the response to 5-FU-based chemotherapy in patients with metastatic CRC. Our results indicate that concomitant low/medium TRAIL-R1 and high TRAIL-R3 expression in primary CRC is significantly associated with a poor response to 5-FU-based first-line chemotherapy and with shorter progression-free survival. Then, by combining the levels of

Conflict of interest statement

None declared.

Acknowledgement

This work was supported by the French Ministry of Health (Programme Hospitalier de Recherche Clinique – PHRC Régional 2003).

References (33)

  • A. Ashkenazi et al.

    Safety and antitumor activity of recombinant soluble Apo2 ligand

    J Clin Invest

    (1999)
  • B. Gliniak et al.

    Tumor necrosis factor-related apoptosis-inducing ligand’s antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11

    Cancer Res

    (1999)
  • E.G. de Vries et al.

    Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications

    Clin Cancer Res

    (2006)
  • D. Cunningham et al.

    Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

    New Engl J Med

    (2004)
  • H. Hurwitz et al.

    Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

    New Engl J Med

    (2004)
  • T. Naka et al.

    Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients’ colon tumors grown in SCID mice

    Cancer Res

    (2002)
  • View full text